Biliary tract cancers (BTC), a heterogeneous disease with poor prognosis, including gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (ECC). Although surgery is currently the primary regimen to treat BTC, most BTC patients are diagnosed at an advanced stage and miss the opportunity of surgical eradication. As a result, non-surgical therapy serves as the main intervention for advanced BTC. In recent years, immunotherapy has emerged as one of the most promising therapies in a number of solid cancers, and it includes immune checkpoint inhibitors (ICIs) monotherapy or combined therapy, tumor vaccines, oncolytic virus immunotherapy, adoptive cell therapy (ACT), and cytokine therapy. However, these therapies have been practiced in limited clinical settings in patients with BTC. In this review, we focus on the discussion of latest advances of immunotherapy in BTC and update the progress of multiple current clinical trials with different immunotherapies.

Objective:To explore the method and effect of endovascular treatment to innominate artery stenosis or occlusion.Methods:The data of 11 patients with stenosis or occlusion of innominate artery from January 2014 to November 2019 at Xuanwu Hospital of Capital Medical University were collected. All patients received endovascular treatment. We summarized the changes of clinical symptoms, surgical methods, perioperative complications, stent patency, and analyzed the changes in systolic blood pressure and peak blood flow velocity on the involving side.Results:All 11 patients underwent endovascular treatment. The surgical technique success rate was 100%. All patients were followed up. The follow-up time was 4-69 months, with an average of (30.1±23.4)months. 2 patients used cerebral umbrella during the operation. 1 patient was performed ipsilateral carotid endarterectomy, 1 patient underwent contralateral carotid stent implantation, 1 patient was diagnosed as severe stenosis of the innominate artery and left common carotid artery, and an innominate artery stent implantation was performed at one stage, left common carotid artery stent implantation was performed after half a year. We done operation from the femoral artery puncture approach (6 patients), brachial artery puncture approach (2 patients), axillary artery and femoral artery puncture approach (1 patients), and right common carotid artery and the femoral artery puncture approach (2 patients). 3 patients had in-stent restenosis at 6, 7and 12 months after stenting, respectively. 1 patient underwent balloon dilatation, and 2 patients underwent re-stent implantation. We have not do further intervention to 1 case of in-stent occlusion occurred 14 months after the stenting, for the clinical symptoms did not improve significantly. The clinical re-intervention rate in this group was 3/11, and the primary patency rate was 7/11. The secondary patency rate was 10/11. The symptoms of 10 patients were relieved and the weakness of right upper extremity was not significantly changed in 1 patient. No puncture point complications occurred in all patients, and no cerebral infarction occurred during the perioperative period. There were statistically significant differences in systolic blood pressure, blood pressure difference and peak blood flow velocity before and after the operation ( P<0.05). Conclusions:Endovascular treatment of innominate arterial stenosis or occlusion was safe and effective, and the appropriate surgical approach and plan should be selected according to the lesion characteristics and the whole body conditions.

Objective:To investigate the early effect of repairing acetabular cartilage delamination with absorbable anchor under hip arthroscopy compared with conventional non-intervention.Methods:Retrospective cohort study was adopted. There were 24 Femoroacetabular Impingment (FAI) patients with acetabular cartilage delamination (ACD) receiving hip arthroscopy surgery in Peking University Third Hospital from May 2021 to August 2021. There were 14 males and 10 females with an average age of 36.3±7.2 years (range 23-53 years). There were 12 patients receiving acetabular cartilage repair with absorbable anchor (absorbable anchor group), and 12 patients in non-intervention group. The X-ray film indicators, α angle, lateral center edge angle (LCEA) and MRI measurement (acetabular cartilage gap, CG) were compared between the two groups. The pre- and post-operative hip functions were assessed by modified Harris Hip Score (mHHS), 12-item international hip outcome tool (iHOT12), hip outcome score-activities of daily living subscale (HOS-ADL), and hip outcome score-sports subscale (HOS-SS), along with visual analogue scale (VAS). The complications (infection, lower extremity deep venous thrombosis) were followed up, as well as the revisional hip arthroscopy surgery and total hip replacement surgery.Results:A total of 24 patients were followed up for 12.0±1.2 months (range 10-14 months). There was no significant difference between the two groups for age, BMI, and symptom onset time ( P>0.05). There was no significant difference between the two groups for the pre-operative α angle, LCEA, CG, mHHS, iHOT12, HOS-ADL, HOS-SS, and VAS scores ( P>0.05). At the last follow-up, there was no significant difference between the two groups for the α angle, LCEA, CG, mHHS, iHOT12, HOS-ADL, HOS-SS, VAS and satisfaction ( P>0.05). In the absorbable anchor group, the α angle was 47.2°±2.6° vs. 63.4°±3.3°, CG was 3.0±0.7 mm vs. 3.3±0.6 mm; mHHS was 73.6±16.0 vs. 57.7±15.4; iHOT12 was 67.6±22.5 vs. 50.6±15.0 after and before the surgery, with significant improvement ( P<0.05). As for the non-intervention group, there was significant decrease of post-operative α angle of 47.4°±2.6° compared to the pre-operative angle of 58.4°±8.1° ( P<0.05). There was no significant difference in LCEA, CG, mHHS, iHOT12, HOS-ADL, HOS-SS, and VAS scores before and after the surgery in non-intervention group comparison ( P>0.05). No complications, revision hip arthroscopy surgery or total hip replacement surgery occurred during the follow up. Conclusion:Good effect was yielded for absorbable anchor repairing acetabular cartilage delamination under hip arthroscopy, without additional risk of complications or revision surgery.

Congenital insensitivity to pain with anhidrosis (CIPA) is associated with Charcot arthropathy and is a rare clinical syndrome, with limited treatment options. Through a decade-long follow-up of a single case, we aim to provide new insights for clinicians regarding the choice of surgical strategies and postoperative complications. The diagnosed patient exhibited congenital insensitivity to pain and anhidrosis, accompanied by severe Charcot arthropathy affecting the spine. Multiple postoperative complications, including implant displacement, adjacent segment pathology, and pedicle screw loosening, occurred after surgical intervention, leading to five subsequent revision surgeries. Considering the limited experience in managing CIPA-related Charcot spinal arthropathy in the literature, surgical correction remains the preferred treatment. Among the 16 cases reviewed, common postoperative complications included implant displacement, adjacent segment pathology, and pedicle screw loosening. Based on current experience, we do not recommend extensive resection and reconstruction after removing the affected vertebral body, as this may increase the risk of implant displacement. Instead, a 360° long-segment fusion may help reduce the risk of adjacent segment degeneration. Additionally, we discuss potential reasons for revision surgery after Charcot spinal arthropathy surgery and perioperative management strategies for such cases. Meticulous care, appropriate rehabilitation exercises, and metabolic therapy for bone mineralization are crucial components of the treatment for this condition.

A young female patient presented with fever, arthralgia, and rash was diagnosed with adults still's disease. When treated with glucocorticoid steroid, the above patient progressed to anuria, sudden, and confusion. After a teamwork involving different departments, the patient was finally diagnosed with atypical hemolytic uremic syndrome (aHUS) and treated with good outcome. aHUS is a rare disease, while Eculizumab is an orphan drug. The diagnosis and treatment of the patient reveals the importance of multidisciplinary team on the diagnosis and treatment of rare and difficult diseases.